Insulet (PODD) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Insulet (NASDAQ: PODD) in the last few weeks:

• 5/20/2026 – Insulet is now covered by William Blair. They set an “outperform” rating on the stock.
• 5/18/2026 – Insulet had its price target lowered by Bank of America Corporation from $288.00 to $208.00. They now have a “buy” rating on the stock.
• 5/15/2026 – Insulet was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 5/12/2026 – Insulet is now covered by Benchmark Co.. They set a “buy” rating on the stock.
• 5/9/2026 – Insulet was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/7/2026 – Insulet was given a new $237.00 price target by The Goldman Sachs Group, Inc..
• 5/7/2026 – Insulet had its price target lowered by Royal Bank Of Canada from $325.00 to $280.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Truist Financial Corporation from $315.00 to $250.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Sanford C. Bernstein from $330.00 to $200.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Barclays PLC from $286.00 to $198.00. They now have an “underweight” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Stifel Nicolaus from $350.00 to $250.00.
• 5/7/2026 – Insulet had its price target lowered by Raymond James Financial, Inc. from $355.00 to $263.00.
• 5/7/2026 – Insulet had its price target lowered by Evercore Inc from $240.00 to $200.00.
• 5/7/2026 – Insulet had its price target lowered by Canaccord Genuity Group Inc. from $435.00 to $249.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Leerink Partners from $360.00 to $247.00.
• 5/7/2026 – Insulet had its price target lowered by Jefferies Financial Group Inc. from $400.00 to $360.00.
• 5/7/2026 – Insulet had its price target lowered by Citigroup Inc. from $230.00 to $175.00.
• 5/7/2026 – Insulet had its price target lowered by Robert W. Baird from $360.00 to $248.00.
• 5/7/2026 – Insulet had its price target lowered by JPMorgan Chase & Co. from $340.00 to $275.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Oppenheimer Holdings, Inc. from $300.00 to $210.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Insulet had its “neutral” rating reaffirmed by Citigroup Inc..
• 5/6/2026 – Insulet had its price target lowered by Piper Sandler from $360.00 to $210.00.
• 5/6/2026 – Insulet had its price target lowered by Wells Fargo & Company from $360.00 to $255.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Insulet had its price target lowered by BTIG Research from $320.00 to $260.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Insulet was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 4/24/2026 – Insulet had its “neutral” rating reaffirmed by Rothschild & Co Redburn. They now have a $220.00 price target on the stock, down from $380.00.
• 4/24/2026 – Insulet was downgraded by Rothschild & Co Redburn from “buy” to “neutral”. They now have a $220.00 price target on the stock, down from $380.00.
• 4/15/2026 – Insulet had its price target lowered by Truist Financial Corporation from $360.00 to $315.00. They now have a “buy” rating on the stock.
• 4/14/2026 – Insulet had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $325.00 price target on the stock.
• 4/13/2026 – Insulet had its price target lowered by BTIG Research from $380.00 to $320.00. They now have a “buy” rating on the stock.
• 4/8/2026 – Insulet had its price target lowered by The Goldman Sachs Group, Inc. from $326.00 to $277.00. They now have a “buy” rating on the stock.
• 4/7/2026 – Insulet was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $230.00 price target on the stock, down from $338.00.
• 4/6/2026 – Insulet had its price target lowered by Evercore Inc from $340.00 to $240.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue bought 2,030 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is currently owned by company insiders.

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.